Dr. Larry D. Cripe, MD

Dr. Cripe practices at IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health.

Dr. Cripe's NPI, 1225094741, was assigned on April 24, 2006. Dr. Cripe graduated from Rush Medical College of Rush University in 1984. Dr. Cripe holds Indiana license 01043526A.

Dr. Cripe's primary practice is IU Health Methodist Hospital, at 1701 N Senate Blvd, Indianapolis, IN 46202 in Marion County. The practice phone is (317) 962-2000.

Dr. Cripe's primary practice is IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health. Dr. Cripe is also affiliated with IU Health Ball Memorial Hospital. The medical group on file is IU Health Medical Group. Dmand AI also links Dr. Cripe to 3 more hospitals, 2 group practices and clinics, 1 behavioral health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cripe practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Cripe's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Cripe is licensed in Indiana.

CMS data shows 359 Medicare services from Dr. Cripe across 6 procedure codes in 2024, for 171 Medicare patients. Medicare paid $29,857 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 171 Medicare patients who saw Dr. Cripe in 2024. The largest group is 65 to 74, with 100 patients. 71% of them have high blood pressure, and 69% have high cholesterol. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cripe's median patient age at 64, with 55% women.

In 2024, Dr. Cripe wrote 717 Medicare Part D claims for 82 patients. 59% of them were for generic drugs. CMS names the drug for 533 of them, across 20 drugs with 11 or more claims each, at $3,262,722 in total drug cost. In 2023, CMS named 435 claims across 17 drugs.

Dr. Cripe accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cripe as offering telehealth.

Dmand AI links 46 papers to Dr. Cripe, published from 2005 to 2024. 2016 was the busiest year, with 5. The most frequent topics are Leukemia, Myeloid, Acute, Terminal Care and Antineoplastic Combined Chemotherapy Protocols. Dr. Cripe has published most often in Am J Hosp Palliat Care. Dr. Cripe's most frequent co-authors are Martin S. Tallman, MD, Hugo Francisco Fernandez, MD and Mark R. Litzow, MD.

Dmand AI links Dr. Cripe to 4 clinical trials, 2 of them phase 2/3 studies. 3 are still active or recruiting. Conditions studied include Myelodysplastic Syndromes, GATA2 Deficiency and Leukemia, Myeloid, Acute. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 7 general payments to Dr. Cripe from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. Celgene Corporation paid the most, $1,978.

Dr. Cripe graduated from Rush Medical College of Rush University in 1984.